URGNUroGen Pharma Ltd.

$918M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$372,000+1966.7% YoY

Gross Profit

$324,00087.1% margin

Operating Income

-$32M-8548.4% margin

Net Income

-$31M-8427.2% margin

EPS (Diluted)

$-1.44

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$161M

Total Liabilities

$18M

Stockholders' Equity

$143M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$372,000	$18,000	+1966.7%
Gross Profit	$324,000	$18,000	+1700.0%
Operating Income	-$32M	-$24M	-33.9%
Net Income	-$31M	-$22M	-39.5%

URGN Q2 2020 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena